SELLAS Life Sciences shares drop 14% amid REGAL delay, challenging $2.2 billion valuation
SELLAS Life Sciences (NASDAQ:SLS) shares fell about 14% after investors awaited updates on its REGAL Phase 3 trial in acute myeloid leukemia. The stock closed at $11.32. SELLAS said REGAL will proceed to final analysis after the 80th death event, with 78 events reported as of May 11. The company cited a $2.2B equity valuation and noted a $150M ATM facility remained unused.
How this was made
The 30-second read
Why it matters
The market is repricing around the probability-weighted timing and outcome of REGAL, since the next major catalyst is the disclosure of the 80th event and subsequent unblinding.
Market read
A milestone-gated Phase 3 update delay is the direct driver of the stock’s sharp decline, making timing and dilution risk the key trading variables.
What to watch
The article flags dilution risk from warrant exercises/ATM usage, but it also states the ATM was unused as of May 12, which could reduce near-term dilution pressure if financing needs remain low.
Background
REGAL is a Phase 3 randomized trial in acute myeloid leukemia evaluating galinpepimut-S, with results gated by reaching 80 death events and remaining blinded until database lock.
Ticker impact
SELLAS shares fell 14% as investors waited for REGAL Phase 3 updates, with the 80th death threshold still pending and study blinded.
Elevated volatility likely into the next disclosed REGAL milestone, with downside risk if event timing slips or dilution via ATM/warrants increases.
The article ties the selloff directly to REGAL delay risk and explains the 80th-death trigger for database lock and unblinding, which governs the next major catalyst.
Market effects
Highlights how binary Phase 3 event-driven timelines can rapidly reprice biotech valuations when milestones slip or remain blinded.
Primarily impacts US biotech sentiment and Nasdaq small/mid-cap risk appetite around clinical readouts.
Limited beyond biotech investors tracking AML trial timelines and valuation sensitivity to clinical endpoints.
Counterpoint
The stock’s move may over-discount the probability of failure because the article also notes a new financing and an unused $150M ATM, which can fund operations through the next readout.
Key entities
- public_companySELLAS Life Sciences Group
NASDAQ-listed biotech whose shares dropped 14% amid investor caution over REGAL program updates and the 80th-death milestone.
- clinical_trialREGAL program
Phase 3 trial in AML where database lock and unblinding occur after the 80th death event is reported.
- clinical_programSLS009
Phase 2 AML program with initial results anticipated in Q4 2026, providing an additional pipeline catalyst.
- executiveAngelos Stergiou
CEO quoted describing the upcoming REGAL milestone as important, without specifying a REGAL date.
